Popular Articles
Stretch Mark

Massachusetts Could Provide Model To Pay For Reform
USA Today reports that three years after mandating coverage for all, Massachusetts is emerging as national model.
generic viagra online
Civilian Doctors, Not Just Those In Combat Settings, Urgently Need Training On Blast Injuries
The increasing incidence of terrorist attacks means that doctors in civilian settings, as well as those in combat operations, need training on blast injuries. The issues surrounding these frequently devastating injuries are discussed in a Seminar published Online First and in an upcoming edition of The Lancet, written by Dr Stephen Wolf, Department of Emergency Medicine, Denver Health Medical Center, Denver, CO, USA, and colleagues.
News of the day
Columnists Respond To Selection Of Sotomayor As Supreme Court Nominee
The New York Times, Washington Post and Washington Times recently published opinion pieces on President Obama"s nomination of Judge Sonia Sotomayor to the Supreme Court. Summaries appear below.~ David Brooks, New York Times: "Supreme Court justices, like all of us, are emotional intuitionists" because "they begin their decision-making processes with certain models in their heads," Times columnist Brooks writes, adding that "[t]hese are models of how the world works and should work, which have been idiosyncratically ingrained by genes, culture, education, parents and events," and which "shape the way judges perceive the world." Therefore, the "crucial question in evaluating a potential Supreme Court justice ... is not whether she relies on empathy or emotion, but how she does so," according to Brooks. He writes that Sotomayor "will be a good justice if she can empathize with the many types of people and actions involved in a case, but a bad justice if she can only empathize with one type, one ethnic group or one social class." He concludes, "It"s not whether judges rely on emotion and empathy, it"s how they educate their sentiments within the discipline of manners and morals, tradition and practice" (Brooks, New York Times, 5/29).~ Michael Gerson, Washington Post: By opposing Sotomayor"s confirmation, Republicans could be entering "a trap" by "further alienating Hispanic voters the GOP has recently driven away in droves," which might "confirm an image of Republicans as the party of the male and pale," columnist Gerson writes in a Post opinion piece. He continues, "Barring unforeseen ethical revelations, opposition to Sotomayor seems both politically risky and ultimately futile." However, "Republicans must still enter the trap -- with open eyes and no expectation of gain -- not to defeat a nominee but to maintain a principle" that the court "should be a place where all are judged impartially, as individuals," Gerson writes. He continues that the "Obama/Sotomayor doctrine of empathy challenges this long-established belief," and this "is not a minor matter." According to Gerson, "Concerns about the doctrine of empathy will not defeat Sotomayor -- and perhaps they should not defeat her." However, the "problems raised by selective empathy require a substantive (not harsh or personal) national debate -- and this requires Republicans to carefully, warily, enter Obama"s trap" (Gerson, Washington Post, 5/29).~ Michael Kinsley, Washington Post: "What conservative Republicans don"t like about the Supreme Court can be summarized as three, or maybe four, A"s: abortion, affirmative action and activism," columnist Kinsley writes in a Post opinion piece. He adds that "[r]ecent Republican platforms have pledged to appoint judges who not only will overturn Roe [v. Wade] but will make clear that fetuses have the same rights as people under the 14th Amendment"s guarantee of "equal protection of the laws."" Kinsley continues that supporters of Roe "clearly represent the "activist" side," while opponents of the decision "are right that Roe represents the highest tide of Warren Court activism." However, this "doesn"t mean the critics of Roe are right on the merits;" rather, it means that ""activism" is a near-worthless concept, and comparative activism is nonsense," Kinsley writes. He continues, "Although I am pro-choice, Roe makes me unhappy because it was poorly reasoned, not because it "went further" than other decisions." According to Kinsley, "many opponents of Roe would not be satisfied with merely seeing it overturned and the issue returned to the states," and, in fact, the GOP platform "effectively calls for a litmus test for judges: Will they rule abortion illegal in all 50 states no matter what the people want?" He continues, "Now that would be judicial activism with a vengeance" (Kinsley, Washington Post, 5/29).~ Eugene Robinson, Washington Post: The fact that Sotomayor "is a proud and accomplished Latina" apparently "drives some prominent Republicans into a s
Health Insurance

Funxional Successfully Completes Initial Clinical Trial Of FX125L, An Anti-Inflammatory Drug With A Novel Mechanism Of Action

Funxional Therapeutics Ltd (Funxional) has announced the successful completion of the first Phase I study with FX125L, an orally available small molecule which belongs to a new therapeutic class named Broad Spectrum Chemokine Inhibitors (BSCIs). The Phase I, single ascending dose study was conducted in the United States. FX125L was well tolerated at all doses studied and no serious adverse events or subject withdrawals were observed. The pharmacokinetics of FX125L was linear over the wide dose range studied and consistent with once-daily oral dosing for patients. "We are extremely pleased with the outcome of this initial clinical study with FX125L," said Konstantinos Efthymiopoulos, CEO of Funxional Therapeutics. "The results in humans are consistent with the preclinical data, suggesting that FX125L has a very wide safety margin, and confirmed the excellent drug-like profile of FX125L." About Funxional Therapeutics Ltd. Funxional Therapeutics is a privately held, clinical stage pharmaceutical company based in Cambridge (UK) which focuses on novel anti-inflammatory therapies. FXT is managed by a very experienced team and is financed by Index Ventures and Novo A/S, while its shareholders also include Ipsen and Cambridge University. FXT has research and office facilities in Cambridge. About BSCIs BSCIs are anti-inflammatory compounds with an entirely novel mechanism of action that involves the selective interaction with a well-characterized receptor, resulting in a potent inhibition of inflammatory cell migration. The compounds are anticipated to have broad applicability in inflammatory diseases. BSCIs are one of the three proprietary technology platforms in FXT"s portfolio all of which originated in the University of Cambridge. BSCIs were discovered based upon a strategy that exploits functional screening to develop novel new classes of drugs. FX125L is the lead drug candidate in this novel class, while other BSCIs have been identified as back up molecules or as candidates for development as topical anti-inflammatory agents. Funxional Therapeutics Limited


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):